IAMOG
NBIX icon

Investors Asset Management of Georgia’s Neurocrine Biosciences NBIX Stock Holding History

Investors Asset Management of Georgia’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-202
Closed -$21K – 397
2022
Q3 		$21K Hold
202
– – 0.01% 396
2022
Q2 		$20K Buy
+202
New +$18.6K 0.01% 339

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Investors Asset Management of Georgia's NBIX Position: Q4 2022 in Review

Investors Asset Management of Georgia sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 202 shares — an estimated $21K sold.

Investors Asset Management of Georgia first reported a position in NBIX in Q2 2022 and held it in 2 quarters. The position peaked at $21K in Q3 2022. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

  • Investors Asset Management of Georgia reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
  • Investors Asset Management of Georgia sold 202 Neurocrine Biosciences shares in Q4 2022, an estimated $21K.
  • Investors Asset Management of Georgia first reported a position in Neurocrine Biosciences in Q2 2022 and held it in 2 quarters.
  • Investors Asset Management of Georgia's Neurocrine Biosciences position peaked at $21K in Q3 2022.
  • 529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Investors Asset Management of Georgia's 13F filing for Q4 2022, filed 2 Feb 2023.